Sharon Benzeno Sells Shares in Adaptive Biotechnologies
Sharon Benzeno, Chief Commercial Officer at Adaptive Biotechnologies, sold shares worth $231,714.
Key Points
- Sharon Benzeno, Chief Commercial Officer at Adaptive Biotechnologies, sold 11,034 shares on June 26, 2026, for $231,714.
- Adaptive Biotechnologies' stock traded at $21.03 on Wednesday, with a market cap of $3.35 billion and a 52-week high of $21.01.
- Analysts maintain a strong buy consensus with a target mean price of $20.29, as insiders continue trading activity.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Sharon Benzeno, the Chief Commercial Officer of Immune Medicine at Adaptive Biotechnologies Corporation, sold 11,034 shares of the company on June 26, 2026. The shares were sold at an average price of $21.00, totaling $231,714. This transaction was part of a planned trading activity.
Insider Buying and Selling at Adaptive Biotechnologies Corporation
Benzeno's recent sale was part of a series of transactions. On June 29, 2026, she sold an additional 154,768 shares at $21.14, and also executed a purchase of 103,295 shares at $7.28. These trades reflect ongoing insider activity, with some trades planned and others not.
Adaptive Biotechnologies Corporation Stock Down 15.6%
Shares of NasdaqGS:ADPT traded near $21.03 on Wednesday. The company, which operates in the healthcare sector focusing on diagnostics and research, has a market capitalization of approximately $3.35 billion. Adaptive Biotechnologies is not currently profitable, reflected by its negative forward P/E ratio. The stock has traded between $9.96 and $21.01 over the past year, with a 50-day moving average of $15.32 and a 200-day moving average of $15.62.
$ADPT stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 29, 2026, Guggenheim maintained its buy rating on Adaptive Biotechnologies, setting a price target of $22.00. Other analysts, including Morgan Stanley and JP Morgan, have also maintained their ratings, reflecting a consensus target mean price of $20.29 among seven analysts. The consensus recommendation remains strong buy.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, headquartered in Seattle, Washington, is a commercial-stage company specializing in immune medicine platforms for diagnosing and treating diseases. The company utilizes its proprietary immunosequencing platform and offers the clonoSEQ diagnostic test, which monitors minimal residual disease in cancer patients. Led by CEO Chad M. Robins, the company employs around 624 people and focuses on life sciences research, clinical diagnostics, and drug discovery.
Bottom Line
Sharon Benzeno's recent sale of shares highlights ongoing insider trading activity at Adaptive Biotechnologies. Investors often track such trades for potential insights, although insider selling alone doesn't indicate future stock performance. As the company continues to develop its immune medicine platform, analysts maintain a positive outlook with a strong buy consensus.
Get Adaptive Biotechnologies Corporation alerts
New 13F filings, insider trades, and analyst moves on $ADPT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.